DEA

Medical Cannabis Operators Rush to Register with DEA Post-Rescheduling

Medical cannabis operators are rushing to register with the DEA following marijuana rescheduling, hoping to secure 280E tax relief despite unclear federal guidance on whether registration will be mandatory.

May 14, 2026

DEA Expands Registration Forms to Cannabis Manufacturers and Labs

DEA will soon release federal registration forms for cannabis manufacturers, distributors, and testing labs, expanding beyond last month's dispensary-only registration as marijuana moves toward Schedule III reclassification.

May 12, 2026

White House Drug Strategy Contradicts Trump Cannabis Policy Moves

The White House's new drug strategy warns against cannabis liberalization while the administration simultaneously advances marijuana rescheduling, creating policy confusion that experts say undermines federal credibility.

May 11, 2026

Oklahoma Requires Cannabis Businesses to Register With DEA or Face State Penalties

Oklahoma's narcotics bureau is requiring medical marijuana businesses to register with the federal DEA or risk losing their state licenses, creating new compliance challenges for operators.

May 9, 2026

Target Expands Hemp THC Drinks to 300+ Stores Ahead of Federal Ban

Target is expanding hemp THC beverages to 300+ stores in Florida, Texas, and Illinois despite a federal ban potentially taking effect within six months—a move that raises questions about the retail giant's regulatory outlook.

May 8, 2026

DEA Portal Draws 400 Cannabis Operators in First Three Days

Nearly 400 cannabis businesses registered with the DEA's new portal in 72 hours, racing to meet a June 26 deadline for 280E tax relief under Schedule III rescheduling.

May 5, 2026

DEA Officially Classifies HHC as Schedule I Controlled Substance

DEA formally classifies HHC as Schedule I controlled substance, declaring the synthetic cannabinoid illegal despite hemp origins and closing a loophole manufacturers used to market products as legal alternatives.

May 3, 2026

Big Pharma Eyes Cannabis as Schedule III Move Draws New Investment

Pharmaceutical companies and institutional investors are reassessing cannabis opportunities as federal rescheduling advances, potentially bringing new capital but also competition to the marijuana industry.

May 1, 2026

House Republicans Push Rescheduling Block Despite Trump's Support

House Republicans advance appropriations language blocking marijuana rescheduling funds, contradicting Trump administration's stated support for moving cannabis to Schedule III.

Apr 30, 2026

DEA Opens Federal Registration Portal for State-Licensed Dispensaries

The DEA's new online registration portal allows state-licensed medical marijuana dispensaries to apply for federal protections under Schedule III, marking a historic shift in federal cannabis policy.

Apr 30, 2026

South Carolina's Medical Cannabis Law May Have Activated Under Rescheduling

Federal marijuana rescheduling may have accidentally activated South Carolina's dormant medical cannabis program due to conditional language in the state's 2023 law that tied implementation to federal scheduling status.

Apr 29, 2026

Trump Administration Moves Cannabis to Schedule III in Partial Win

The Trump administration rescheduled cannabis to Schedule III, providing tax relief to licensed operators but stopping short of full legalization. The move leaves banking restrictions and federal prohibition intact.

Apr 24, 2026

Cannabis Operators Pivot Strategy as Schedule III Decision Looms

Cannabis companies are pursuing clinical trial partnerships and expansion strategies in anticipation of marijuana's potential rescheduling to Schedule III, even as the DEA's final decision timeline remains uncertain.

Apr 24, 2026

DEA Faces Mounting Credibility Crisis as Cannabis Rescheduling Looms

The DEA's history of corruption cases and oversight failures is raising questions about its role in cannabis rescheduling decisions, even as the agency weighs a recommendation to move marijuana to Schedule III.

Apr 11, 2026

WSJ Pushes Teen Access Narrative Despite Federal Data Showing Decline

The Wall Street Journal links teen cannabis access to legalization despite DEA data showing youth use has declined. Federal surveys contradict the newspaper's framing as regulated markets expand nationwide.

Mar 21, 2026

Pennsylvania Senate Targets Hemp THC Products in Amended Cannabis Bill

Pennsylvania Senate committee amends cannabis bill to ban most hemp THC products, aligning with federal DEA rule changes taking effect in November.

Mar 17, 2026

Trump's Medical-Only Cannabis Language Raises Rescheduling Questions

Trump's executive order on marijuana rescheduling specifically mentions only medical cannabis, raising questions about whether federal reform will exclude the $33 billion adult-use industry.

Jan 24, 2026

AG Bondi Misses Deadline on Schedule I Research Rules

Attorney General Pam Bondi has missed a federal deadline to publish new rules making it easier for researchers to study Schedule I drugs like cannabis and psychedelics, leaving scientists waiting for promised regulatory relief.

Jan 21, 2026